BioPharmSignal logoBioPharmSignal

Biotech News

Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials

Kiora Pharmaceuticals (KPRX)Kiora PharmaceuticalsClinical readout

KPRX (KPRX) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is kprx.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

KPRXKiora Pharmaceuticals2026-04-14 11:00 EST

Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway

KPRXKiora Pharmaceuticals2026-08-07 11:00 EST

Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

PRQRProQR Therapeutics2026-04-08 20:00 EST

ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event

TARSTarsus Pharmaceuticals2026-03-31 12:30 EST

Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

BLTEBelite Bio2026-07-20 12:00 EST

Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1

OCSOculis2026-05-29 19:06 EST

Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema

MGTXMeiraGTx2026-04-16 11:00 EST

MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia

MGTXMeiraGTx2026-04-14 12:30 EST

MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026

OCGNOcugen2026-04-01 11:02 EST

Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease

OKYOOKYO Pharma2026-07-20 11:00 EST

OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 Plans

View all latest news

Kiora Pharmaceuticals

Retinal-Disease Pipeline Kiora Pharmaceuticals develops small-molecule therapies for retinal diseases. Its programs are designed to improve vision or preserve retinal function through mechanisms distinct from conventional gene-specific approaches. KIO-301 KIO-301 is a light-sensitive small molecule intended to restore visual signaling in...

Recent company news

KPRXKiora Pharmaceuticals2026-08-07 11:00 EST

Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

KPRXKiora Pharmaceuticals2026-07-02 11:00 EST

Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium

KPRXKiora Pharmaceuticals2026-06-18 11:00 EST

Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model

KPRXKiora Pharmaceuticals2026-05-08 11:00 EST

Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

KPRXKiora Pharmaceuticals2026-04-14 11:00 EST

Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway

Stock data

Close
2.56 USD
Market cap
12.05M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States